TW202116781A - 新穎雜環化合物 - Google Patents

新穎雜環化合物 Download PDF

Info

Publication number
TW202116781A
TW202116781A TW109123050A TW109123050A TW202116781A TW 202116781 A TW202116781 A TW 202116781A TW 109123050 A TW109123050 A TW 109123050A TW 109123050 A TW109123050 A TW 109123050A TW 202116781 A TW202116781 A TW 202116781A
Authority
TW
Taiwan
Prior art keywords
chloro
compound
formula
group
phenyl
Prior art date
Application number
TW109123050A
Other languages
English (en)
Chinese (zh)
Inventor
卡斯頓 克羅
芙洛爾 瑞吉安尼
米洛史雷夫 寇莎爾
摩瑞斯 彼得曼
伯恩德 庫恩
貝諾伊特 賀恩斯伯格
烏威 葛瑞瑟
費歐恩 歐哈拉
漢斯 雷卻特
Original Assignee
瑞士商赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67220669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW202116781(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 瑞士商赫孚孟拉羅股份公司 filed Critical 瑞士商赫孚孟拉羅股份公司
Publication of TW202116781A publication Critical patent/TW202116781A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW109123050A 2019-07-09 2020-07-08 新穎雜環化合物 TW202116781A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19185088.2 2019-07-09
EP19185088 2019-07-09

Publications (1)

Publication Number Publication Date
TW202116781A true TW202116781A (zh) 2021-05-01

Family

ID=67220669

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109123050A TW202116781A (zh) 2019-07-09 2020-07-08 新穎雜環化合物

Country Status (19)

Country Link
US (1) US20220242876A1 (https=)
EP (1) EP3997096B1 (https=)
JP (1) JP7649283B2 (https=)
KR (1) KR20220034104A (https=)
CN (1) CN114096545A (https=)
AR (1) AR119376A1 (https=)
AU (1) AU2020311584A1 (https=)
BR (1) BR112021026899A2 (https=)
CA (1) CA3145338A1 (https=)
CL (1) CL2022000019A1 (https=)
CO (1) CO2022000186A2 (https=)
CR (1) CR20220004A (https=)
IL (1) IL288987A (https=)
MX (1) MX2022000243A (https=)
PE (1) PE20220515A1 (https=)
PH (1) PH12021553249A1 (https=)
TW (1) TW202116781A (https=)
WO (1) WO2021005034A1 (https=)
ZA (1) ZA202110352B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
PE20211089A1 (es) 2018-08-13 2021-06-14 Hoffmann La Roche Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa
WO2020104494A1 (en) 2018-11-22 2020-05-28 F. Hoffmann-La Roche Ag New heterocyclic compounds
CN114269755A (zh) 2019-09-12 2022-04-01 豪夫迈·罗氏有限公司 作为magl抑制剂的4,4a,5,7,8,8a-六吡啶并[4,3-b][1,4]噁嗪-3-酮化合物
CA3190277A1 (en) 2020-09-03 2022-03-10 Joerg Benz Heterocyclic compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014001946A (es) * 2011-08-19 2014-03-27 Merck Sharp & Dohme Inhibidores del canal de potasio medularmente externo renal.
US9573961B2 (en) 2012-12-19 2017-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2017087863A1 (en) * 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
EP3571202B1 (en) * 2017-01-23 2021-06-30 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
JOP20190267A1 (ar) * 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl
JP7257387B2 (ja) * 2017-08-29 2023-04-13 ハー・ルンドベック・アクチエゼルスカベット スピロ環化合物並びにその作製及び使用方法
WO2019134985A1 (en) * 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
MX2022000083A (es) * 2019-07-03 2022-02-03 Hoffmann La Roche Inhibidores de monoacilglicerol lipasa (magl) heterociclicos.

Also Published As

Publication number Publication date
PH12021553249A1 (en) 2023-02-27
BR112021026899A2 (pt) 2022-05-10
EP3997096A1 (en) 2022-05-18
ZA202110352B (en) 2022-08-31
CR20220004A (es) 2022-01-31
WO2021005034A1 (en) 2021-01-14
EP3997096C0 (en) 2024-08-28
CL2022000019A1 (es) 2022-10-21
IL288987A (en) 2022-02-01
CO2022000186A2 (es) 2022-01-17
PE20220515A1 (es) 2022-04-07
AR119376A1 (es) 2021-12-15
JP7649283B2 (ja) 2025-03-19
EP3997096B1 (en) 2024-08-28
KR20220034104A (ko) 2022-03-17
MX2022000243A (es) 2022-02-03
JP2022539604A (ja) 2022-09-12
US20220242876A1 (en) 2022-08-04
AU2020311584A1 (en) 2022-01-20
CA3145338A1 (en) 2021-01-14
CN114096545A (zh) 2022-02-25

Similar Documents

Publication Publication Date Title
JP7609854B2 (ja) Magl阻害剤としての4,4a,5,7,8,8a-ヘキサピリド[4,3-b][1,4]オキサジン-3-オン化合物
TWI818967B (zh) 新穎雜環化合物
TWI812770B (zh) 新穎雜環化合物
JP7649283B2 (ja) 新規複素環化合物
US11242334B2 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
JP2021533093A (ja) モノアシルグリセロールリパーゼ阻害剤としての新規複素環化合物
JP2022527590A (ja) モノアシルグリセロールリパーゼ(magl)の阻害剤としての複素環式化合物
JP7669299B2 (ja) 複素環モノアシルグリセロールリパーゼ(magl)阻害剤
CA2935071A1 (en) Piperidine-dione derivatives
CN114401968A (zh) 新颖杂环单酰基甘油脂肪酶(magl)抑制剂
TW201625625A (zh) 做為pde2抑制劑之經取代的[1,2,4]三唑并[1,5-a]嘧啶-7-基化合物
US20260015360A1 (en) Biaryl derivatives and related uses
TW202333664A (zh) 新穎雜環化合物
HK40068386A (en) New heterocyclic compounds
HK40065118A (en) New heterocyclic monoacylglycerol lipase (magl) inhibitors
HK40062310A (en) 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
HK40035599A (en) Oxazine monoacylglycerol lipase (magl) inhibitors